文拉法辛合并喹硫平治疗难治性抑郁症的对照研究

Comparative Study of Venlafaxine Combined with Quetiapine in Treatment of Refractory Depression

目的探讨文拉法辛合并喹硫平治疗难治性抑郁症的安全性和疗效。方法将92例难治性抑郁症患者随机分为2组,研究组采用文拉法辛合并喹硫平治疗,对照组采用文拉法辛治疗,分别在治疗后第2、4、8、12周末,评定汉密顿抑郁量表(HAMD)和临床总体印象量表(CGI),同时采用Asberg抗抑郁剂副反应量表评定2组药物的不良反应。结果根据HAMD评分,2组8周末减分率分别为(31.85±12.78)、(19.00±11.88),2组12周末减分率分别为(48.46±20.75)、(29.54±16.85),2组间差异均具有统计学意义(P<0.05)。根据CGI评分,2组8周末评分分别为(2.31±0.95)、(3.15±1.06),2组12周末评分分别为(2.00±1.00)、(2.99±1.19),2组间差异具有统计学意义(P<0.05)。药物不良反应2组间无明显差异(P>0.05)。结论文拉法辛合并喹硫平治疗难治性抑郁症的疗效好,不良反应无明显增加。

[ Objective ] To explore the safety and efficacy of venlafaxine combined with quetiapine in treatment of refractory depression. [ Methods] A total of 92 patients with refractory depression were randomly divided into 2 groups, the study group was treated with venlafaxine and quetiapinej and the control group used venlafaxine for treatment. All subjects were assessed with HAMD and CGI, Asberg Rating Scale for Side Effects was adopted to evaluate adverse effects of the 2 groups of drugs at the ends of 2nd, 4th, 8th, 12th weeks. [ Results ] According to HAMD score, the rates of decreased scores at the end of 8th week were （31.85 ±12.78） in study group and { 19.00 ± 11.88 } in control group. That at the end of 12th week was （ 48.46 ± 20.75 } and { 29.54 ± 16.85 ） respectively ; the differences between 2 groups were significant （ P 〈 0.05 ）. At the end of 8th week, the scores of CGI were （ 2.31 ± 0.95 ） in study group, （ 3.15 ±1.06 ） in control group and at the end of 12th week were （ 2.00 ± 1.00 ） and { 2.92 ± 1.19 } respectively, there were significant differences between 2 groups （ P 〈 0.05 ）. No significant difference of side effects were found between 2 groups{ P 〉0.05 ）. [ Conclusion] Venlafaxine combined with quetiapine is effective in the treatment of refractory depression, without significant increase in adverse reaction.